Pfizer's annual financial reports or credible market analysis reports

EU Approves Pfizer's Emblaveo for Gram-Negative Bacterial Infections

Apr 22, 2024, 12:41 PM

The European Commission has approved Pfizer's new antibiotic, Emblaveo (aztreonam-avibactam), for treating multidrug-resistant infections caused by Gram-negative bacteria, including hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). This approval, endorsed by the European Medicines Agency, addresses the critical need for treatments against severe infections with limited options.